Clinical Trials Logo

Filter by:
NCT ID: NCT05067127 Active, not recruiting - C3 Glomerulopathy Clinical Trials

Phase III Study Assessing the Efficacy and Safety of Pegcetacoplan in Patients With C3 Glomerulopathy or Immune-Complex Membranoproliferative Glomerulonephritis

VALIANT
Start date: November 12, 2021
Phase: Phase 3
Study type: Interventional

This is a Phase 3 study to assess the efficacy and safety of twice-weekly subcutaneous (SC) doses of pegcetacoplan compared to placebo in patients with C3 glomerulopathy (C3G) or immune-complex membranoproliferative glomerulonephritis (IC-MPGN) on the basis of a reduction in proteinuria.

NCT ID: NCT05065970 Completed - Clinical trials for Immunoglobulin A (IgA) Nephropathy

Clinical Trial to Assess Efficacy and Safety of the Human Anti-CD38 Antibody Felzartamab (MOR202) in IgA Nephropathy

IGNAZ
Start date: August 31, 2021
Phase: Phase 2
Study type: Interventional

Randomized, placebo-controlled, multi-center, double-blind, proof of concept phase IIa trial and dose evaluation trial of felzartamab in IgAN

NCT ID: NCT05065619 Terminated - Clinical trials for SARS-CoV-2 Infection

Safety Immunogenicity Study of MT-2766 in Japanese Adults(COVID-19)

Start date: October 2, 2021
Phase: Phase 1/Phase 2
Study type: Interventional

The objective of this study is to evaluate the safety and immunogenicity of MT-2766 in Japanese adults.

NCT ID: NCT05064878 Recruiting - Clinical trials for CDKL5 Deficiency Disorder

A Study to Investigate the Efficacy and Safety of ZX008 in Subjects With CDKL5 Deficiency Disorder

Start date: March 8, 2022
Phase: Phase 3
Study type: Interventional

This is a multicenter, double-blind, parallel-group, placebo controlled, 2-part study to evaluate the efficacy and safety of ZX008 when used as adjunctive therapy for the treatment of uncontrolled seizures in children and adults with cyclin-dependent kinase like-5 (CDKL5) deficiency disorder (CDD).

NCT ID: NCT05064618 Recruiting - Pancreatic Cancer Clinical Trials

Investigator-initiated Clinical Trial of MIKE-1

MIKE-1
Start date: August 23, 2021
Phase: Phase 1/Phase 2
Study type: Interventional

To evaluate the safety and tolerability of Am80(Generic name: Tamibarotene, Development code: MIKE-1) in combination with gemcitabine (GEM) and nab-paclitaxel (nab-PTX) in patients with unresectable pancreatic cancer and to determine the recommended dose. Efficacy will also be exploratively investigated.

NCT ID: NCT05064371 Active, not recruiting - Migraine Clinical Trials

Long-Term Extension Study With Eptinezumab as Preventive Treatment in Participants With Migraine in Japan

Start date: September 21, 2021
Phase: Phase 3
Study type: Interventional

This study is an open label extension study, which means that the participants from the Lead-in Study 19140A (NCT04921384) can join this study, if they meet the study Eligibility Criteria, and continue to receive the study drug eptinezumab. The main goal of this study is to investigate long-term safety and tolerability of eptinezumab in Japanese migraine participants.

NCT ID: NCT05064059 Active, not recruiting - Colorectal Cancer Clinical Trials

A Study of Coformulated Favezelimab/Pembrolizumab (MK-4280A) Versus Standard of Care in Subjects With Previously Treated Metastatic PD-L1 Positive Colorectal Cancer (MK-4280A-007)

Start date: November 10, 2021
Phase: Phase 3
Study type: Interventional

The purpose of this study is to assess the safety and efficacy of coformulated favezelimab/pembrolizumab (MK-4280A) in participants with metastatic colorectal cancer. The study will also compare MK-4280A with the standard of care treatment of regorafenib and TAS-102 (trifluridine and tipiracil). The primary study hypothesis is that coformulated favezelimab/pembrolizumab (MK-4280A) is superior to standard of care with respect to overall survival.

NCT ID: NCT05063994 Completed - Clinical trials for Congenital Adrenal Hyperplasia

Comparison of Chronocort Versus Standard Hydrocortisone Replacement Therapy in Participants Aged 16 Years and Over With Congenital Adrenal Hyperplasia

CONnECT
Start date: December 13, 2021
Phase: Phase 3
Study type: Interventional

This study is a randomized, double-blind, active-controlled, phase III study of Chronocort® compared with immediate-release hydrocortisone replacement therapy in participants aged 16 years and over with Congenital Adrenal Hyperplasia.

NCT ID: NCT05063539 Active, not recruiting - Alzheimer Disease Clinical Trials

A Study of LY3372689 to Assess the Safety, Tolerability, and Efficacy in Participants With Alzheimer's Disease

Start date: September 16, 2021
Phase: Phase 2
Study type: Interventional

The purpose of this study is to assess the safety, tolerability and effect of study drug LY3372689 in participants with early symptomatic Alzheimer's Disease

NCT ID: NCT05063162 Recruiting - Clinical trials for Myelin Oligodendrocyte Glycoprotein Antibody-associated Disease (MOG-AD)

A Study to Evaluate the Efficacy and Safety of Rozanolixizumab in Adult Participants With Myelin Oligodendrocyte Glycoprotein (MOG) Antibody-associated Disease (MOG-AD)

cosMOG
Start date: February 2, 2022
Phase: Phase 3
Study type: Interventional

The purpose of the study is to evalute the efficacy, safety and tolerability of rozanolixizumab for treatment of adult participants with myelin oligodendrocyte glycoprotein (MOG) antibody-associated disease (MOG-AD).